OBI Pharma Competitors and Similar CompaniesClear all
OBI Pharma's competitors and similar companies include Tanvex BioPharma, FORMA Therapeutics, Calithera Biosciences and La Jolla Pharmaceutical Company.
 Tanvex BioPharma Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs. |  FORMA Therapeutics FORMA Therapeutics is a biopharmaceutical company intended for the discovery, development, and commercialization of transformative medicines. |  Calithera Biosciences Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. |  La Jolla Pharmaceutical Company La Jolla Pharmaceutical is a biopharmaceutical company that is focused on innovative therapeutics for chronic organ failure and cancer. | ||
Founding Date | Founding Date 2002 | Founding Date 2013 | Founding Date 2008 | Founding Date 2010 | Founding Date 1989 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations TW HQ San Diego, US | Locations Taipei, TW HQ New Taipei, TW Irvine, US San Diego, US San Diego, US | Locations Watertown, US HQ | Locations South San Francisco, US HQ | Locations San Diego, US HQ San Diego, US San Diego, US |
Employees | Employees 124 | Employees 13628% decrease | Employees 77 | Employees 798% increase | Employees 9047% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 998.7 m | Valuation ($) 29.2 k | Valuation ($) 171.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) NT$41.5m (FY, 2023) | Revenue (est.) NT$61.4m (FY, 2023) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $75.7m (FY, 2021) |
Cost of goods | Cost of goods NT$115m (FY, 2023) | Cost of goods NT$1.7m (FY, 2023) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit (NT$63.8m) (FY, 2023) | Gross profit NT$61.6m (FY, 2023) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income (NT$1.3b) (FY, 2023) | Net income (NT$2.1b) (FY, 2023) | Net income ($173m) (FY, 2021) | Net income ($39.7m) (FY, 2022) | Net income $19.7m (FY, 2021) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 346.9m | Total funding raised $ 142.5m | Total funding raised $ 105m | Total funding raised $ 22.9m |
For sources of this data, please see the company profile
View Company Profiles
Tanvex BioPharma
HQ
Taipei, TW
Employees
136↓ 28% decrease
Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs.
View companyFORMA Therapeutics
HQ
Watertown, US
Employees
77
FORMA Therapeutics is a biopharmaceutical company intended for the discovery, development, and commercialization of transformative medicines.
View companyCalithera Biosciences
HQ
South San Francisco, US
Employees
79↑ 8% increase
Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer.
View companyLa Jolla Pharmaceutical Company
HQ
San Diego, US
Employees
90↓ 47% decrease
La Jolla Pharmaceutical is a biopharmaceutical company that is focused on innovative therapeutics for chronic organ failure and cancer.
View company